US Treasury proposes a rule to crack down on high-tech investments in China, other adversaries
The proposed Treasury rules would extend outbound-investment controls to biotechnology and other sensitive technology sectors.
TL;DR
- Treasury proposed adding biotechnology to U.S. outbound-investment restrictions involving countries of concern.
- The proposal implements and expands the framework Congress codified in the 2025 COINS Act.
- The rule is still a proposal; the final scope and effect on specific deals remain unresolved.
Treasury proposed rules on October 22 extending outbound-investment controls to biotechnology and other sensitive sectors. AP reported that the framework covers investments involving designated countries of concern, including China. [1]
STAT said the proposal could restrict U.S. financial transactions involving Chinese biotech firms and related manufacturers. Axios also described potential effects on U.S.-China biotech deals. [2] [3]
The proposal follows the 2025 Comprehensive Outbound Investment National Security Act. AP reported that Treasury’s draft uses thresholds and excludes some financial investments, including stock purchases. [1]
The text remains subject to public process and possible changes. Its final reach across biotechnology, licensing and existing commercial relationships is unsettled. [1] [2] [3]
Why it matters
The proposal places cross-border biotech financing and research partnerships inside a national-security framework. Its eventual scope could matter to firms with international pipelines, but the current text is not final.
Editor's note
Cross-checked against AP, STAT and Axios. Described as proposed; not all Chinese biotech deals are prohibited.